Latest Patent Filing News

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Pure Resources has achieved a key early milestone with Oak Ridge National Laboratory confirming the recovery of heavy rare earth elements from garnet concentrate at its Garnet Hills Project. While still at proof-of-concept stage, this validates the potential for a new source of critical minerals.

Starpharma launches a fully underwritten $32 million entitlement offer to fund the Phase 1 trial of its DEP® HER2-Lutetium radiopharmaceutical and accelerate its targeted oncology asset development.

Temas Resources has filed a new patent for extracting chromium using its Regenerative Chloride Leach technology, broadening its critical minerals platform and commercial prospects.

Temas Resources has filed a new patent for its proprietary Regenerative Chloride Leach (RCL) process targeting vanadium extraction, broadening its critical minerals technology portfolio and reinforcing its commercial licensing ambitions.

Pure Resources has achieved peer-reviewed validation and in-house production of carbon nanotube fibre fabrics, demonstrating directional heat routing capabilities that could redefine thermal management in data centres and defence electronics.

Archer Materials has raised $7 million through a placement and launched a $3 million share purchase plan, backing its strategic partnership with IonQ to develop sovereign quantum computing in Australia.

Entropy Neurodynamics has successfully dosed all six participants in the first cohort of its Phase 2 trial for TRP-8803, an intravenous psilocin therapy targeting Binge Eating Disorder. The study demonstrated controlled psychedelic responses, setting the stage for a Data and Safety Monitoring Board review and topline results expected in July 2026.

Biome Australia has launched a multi-centre clinical trial for its proprietary probiotic BMB18, adding a prestigious Greek university to its research network and commencing recruitment within the expected timeline.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

5E Advanced Materials secures a decade-long boric acid offtake agreement and advances boron product development, while reporting a $12.1 million quarterly loss and planning ASX delisting.